Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 5
2007 4
2008 1
2009 3
2010 7
2011 6
2012 4
2013 5
2014 6
2015 7
2016 11
2017 8
2018 7
2019 6
2020 4
2021 3
2022 4
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Cancer therapy and cardiovascular risk: focus on bevacizumab.
Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N. Economopoulou P, et al. Among authors: kentepozidis n. Cancer Manag Res. 2015 Jun 3;7:133-43. doi: 10.2147/CMAR.S77400. eCollection 2015. Cancer Manag Res. 2015. PMID: 26082660 Free PMC article. Review.
A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer.
Carlsson G, Koumarianou A, Guren TK, Haux J, Katsaounis P, Kentepozidis N, Pfeiffer P, Brændengen M, Mavroudis D, Taflin H, Skintemo L, Tell R, Papadimitriou C. Carlsson G, et al. Among authors: kentepozidis n. ESMO Open. 2022 Oct;7(5):100589. doi: 10.1016/j.esmoop.2022.100589. Epub 2022 Sep 29. ESMO Open. 2022. PMID: 36183444 Free PMC article. Clinical Trial.
Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group.
Kokkali S, Saloustros E, Stefanou D, Makrantonakis P, Kentepozidis N, Boukovinas I, Xenidis N, Katsaounis P, Ardavanis A, Ziras N, Christopoulou A, Rigas G, Kalbakis K, Vardakis N, Emmanouilides C, Athanasiadis I, Anagnostopoulos A, Hatzidaki D, Prinarakis E, Simopoulou F, Kotsakis A, Georgoulias V. Kokkali S, et al. Among authors: kentepozidis n. Curr Oncol. 2022 Feb 17;29(2):1237-1251. doi: 10.3390/curroncol29020105. Curr Oncol. 2022. PMID: 35200604 Free PMC article.
Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial.
Koutras A, Zagouri F, Koliou GA, Psoma E, Chryssogonidis I, Lazaridis G, Tryfonopoulos D, Kotsakis A, Res E, Kentepozidis NK, Razis E, Psyrri A, Koumakis G, Kalofonos HP, Dimopoulos MA, Fountzilas G. Koutras A, et al. Among authors: kentepozidis nk. Br J Cancer. 2020 Aug;123(3):355-361. doi: 10.1038/s41416-020-0909-4. Epub 2020 Jun 3. Br J Cancer. 2020. PMID: 32488135 Free PMC article. Clinical Trial.
Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma.
Fountzilas E, Eliades A, Koliou GA, Achilleos A, Loizides C, Tsangaras K, Pectasides D, Sgouros J, Papakostas P, Rallis G, Psyrri A, Papadimitriou C, Oikonomopoulos G, Ferentinos K, Koumarianou A, Zarkavelis G, Dervenis C, Aravantinos G, Bafaloukos D, Kosmidis P, Papaxoinis G, Theochari M, Varthalitis I, Kentepozidis N, Rigakos G, Saridaki Z, Nikolaidi A, Christopoulou A, Fostira F, Samantas E, Kypri E, Ioannides M, Koumbaris G, Fountzilas G, Patsalis PC. Fountzilas E, et al. Among authors: kentepozidis n. Cancers (Basel). 2021 Jan 8;13(2):198. doi: 10.3390/cancers13020198. Cancers (Basel). 2021. PMID: 33429865 Free PMC article.
75 results